Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 7;13(6):1405.
doi: 10.3390/biomedicines13061405.

MAPT Subhaplotypes in Different Progressive Supranuclear Palsy Phenotypes

Affiliations

MAPT Subhaplotypes in Different Progressive Supranuclear Palsy Phenotypes

Monica Gagliardi et al. Biomedicines. .

Abstract

Background: Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder characterized by abnormal tau protein aggregation. The MAPT gene encodes for tau protein. The MAPT locus harbors two major haplotypes, H1 and H2, with H1 and its subhaplotypes being associated with an increased risk of PSP. Methods: In this study, we genotyped rs8070723 in a cohort of 73 PSP patients, including 47 PSP Richardson Syndrome (PSP-RS) and 27 PSP variants (vPSP), and 93 age-matched healthy controls (HC) from Southern Italy. Results: Haplotype analysis identified H1 and H2 haplotypes that conferred a risk (OR, 2.620; 95% CI, 1.399-5.140; p = 0.0035) and a protective effect (OR, 0.370; 95% CI, 0.196-0.695; p = 0.0015), respectively. In addition, we genotyped five MAPT variants (rs1467967, rs242557, rs3785883, rs2471738, and rs7521) that, together with rs8070723, defined H1 subhaplotypes. We identified 18 distinct MAPT H1 subhaplotypes, among which H1j displayed a nominally significant reduced risk of PSP (OR, 0.201; 95% CI, 0.044-0.915; p = 0.0265). Conclusions: These findings reinforce the role of MAPT genetic variation in PSP pathogenesis and highlight the potential impact of haplotype diversity on disease susceptibility.

Keywords: MAPT gene; haplotypes; progressive supranuclear palsy.

PubMed Disclaimer

Conflict of interest statement

Author Basilio Vescio was partially employed by the company Biotecnomed SCaRL, which is a non-profit private research organization. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of haplotype frequencies. The bar plot shows the distribution of MAPT haplotypes across PSP-RS, vPSP, and HC groups. Several H1 subhaplotypes, such as H1e, H1q, H1t, H1z, show different distribution in PSP-RS and vPSP, while the H2 haplotype shows a markedly higher frequency in the HC group, supporting its potential protective role.

References

    1. Schrag A., Ben-Shlomo Y., Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet. 1999;354:1771–1775. doi: 10.1016/S0140-6736(99)04137-9. - DOI - PubMed
    1. Höglinger G.U., Respondek G., Stamelou M., Kurz C., Josephs K.A., Lang A.E., Mollenhauer B., Müller U., Nilsson C., Whitwell J.L., et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 2017;32:853–864. doi: 10.1002/mds.26987. - DOI - PMC - PubMed
    1. Boxer A.L., Yu J.-T., Golbe L.I., Litvan I., Lang A.E., Höglinger G.U. Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16:552–563. doi: 10.1016/S1474-4422(17)30157-6. - DOI - PMC - PubMed
    1. Stamelou M. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov. Disord. 2019;34:1087–1088. doi: 10.1002/mds.27778. - DOI - PubMed
    1. Barbier P., Zejneli O., Martinho M., Lasorsa A., Belle V., Smet-Nocca C., Tsvetkov P.O., Devred F., Landrieu I. Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects. Front. Aging Neurosci. 2019;11:204. doi: 10.3389/fnagi.2019.00204. - DOI - PMC - PubMed

LinkOut - more resources